Liraglutide treatment ameliorated these pathological changes, consistent with previous studies on experimental animals fed HFD.32, 33 The beneficial effects of GLP‐1 receptor agonists on NAFLD in humans have also been demonstrated in several studies.34, 35 The decrease in liver weight in liraglutide‐treated animals may be caused by the amelioration of fatty liver. This evidence concerns the gene GLP1R and Hepatic steatosis.